Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Sun Pharma Drug Patent Portfolio

Sun Pharma owns 19 orange book drugs protected by 78 US patents with Ezallor Sprinkle having the least patent protection, holding only 1 patent. And Levulan with maximum patent protection, holding 16 patents. Given below is the list of Sun Pharma's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12364699 10 Oct, 2044
Active
US12247034 Crystalline form of deuruxolitinib phosphate 10 May, 2044
Active
US12285432 Treatment of hair loss disorders with deuterated JAK inhibitors 11 Aug, 2042
Active
US11857683 Stabilization of phenobarbital sodium for injection 07 Apr, 2042
Active
US12350475 29 Dec, 2041
Active
US11919907 Deuterated JAK inhibitor and uses thereof 21 May, 2041
Active
US11052196 Method of injecting octreotide acetate into the body 03 Nov, 2040
Active
US11246991 Electrolysis-resistant coupling assembly for valves 03 Nov, 2040
Active
US11534553 Method of injecting octreotide acetate into the body 03 Nov, 2040
Active
US10342850 Octreotide injection 15 May, 2038
Active
US10357567 Methods for photodynamic therapy 12 Jan, 2038
Active
US11077192 Methods for photodynamic therapy 12 Jan, 2038
Active
US11135293 Methods for photodynamic therapy 12 Jan, 2038
Active
US11571478 Methods for photodynamic therapy 12 Jan, 2038
Active
US11690914 Methods for photodynamic therapy 12 Jan, 2038
Active
US12296011 Methods for photodynamic therapy 12 Jan, 2038
Active
US10561659 Treatment of hair loss disorders with deuterated JAK inhibitors 04 May, 2037
Active
US12076323 Treatment of hair loss disorders with deuterated JAK inhibitors 04 May, 2037
Active
US10413525 Duloxetine sprinkles 13 Apr, 2037
Active
US10959982 Duloxetine sprinkles 13 Apr, 2037
Active
US11202772 Duloxetine sprinkles 13 Apr, 2037
Active
US12171742 Duloxetine sprinkles 13 Apr, 2037
Active
US9839626 Duloxetine sprinkles 13 Apr, 2037
Active
US10918694 Topical cyclosporine-containing formulations and uses thereof 28 Feb, 2037
Active
US11951153 Topical cyclosporine-containing formulations and uses thereof 28 Feb, 2037
Active
US11446512 Adjustable illuminator for photodynamic therapy and diagnosis 17 Jan, 2037
Active
US11179574 Method of administering 5-aminolevulinic acid (ALA) to a patient 13 Oct, 2036
Active
US11697028 Adjustable illuminator for photodynamic therapy and diagnosis 13 Oct, 2036
Active
US12290700 Adjustable illuminator for photodynamic therapy and diagnosis 13 Oct, 2036
Active
US10172802 Oral pharmaceutical dosage forms of budesonide 09 Sep, 2036
Active
US9707182 Oral pharmaceutical dosage forms of budesonide 09 Sep, 2036
Active
US10266523 Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof 30 Mar, 2036
Active
US10413543 Stable multiparticulate pharmaceutical composition of rosuvastatin 12 Feb, 2036
Active
US9700535 Oral pharmaceutical composition of isotretinoin 04 Aug, 2035
Active
US9750711 Low dose oral pharmaceutical composition of isotretinoin 29 May, 2035
Active
US9962336 Extended release suspension compositions 01 May, 2035
Active
US10292990 Abiraterone steroid formulation 20 May, 2034
Active
US9889144 Abiraterone acetate formulation and methods of use 17 Mar, 2034
Active
US10441630 Topical formulations and uses thereof 23 Aug, 2033
Active
US8980839 Topical aqueous nanomicellar, ophthalmic solutions and uses thereof 23 Aug, 2033
Active
US9937225 Topical formulations and uses thereof 23 Aug, 2033
Active
US9241948 Ready to be infused gemcetabine solution 01 Jul, 2033
Active
US8785427 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives 25 Jul, 2030
Active
US8063043 Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide 15 Sep, 2029
Active
US9629852 Ophthalmic composition comprising a prostaglandin 12 Sep, 2029
Active
US8778999 Non-steroidal anti-inflammatory ophthalmic compositions 07 Aug, 2029
Active
US8178563 Compounds and compositions as hedgehog pathway modulators 24 Jul, 2029
Active
USRE50218 Non-steroidal anti-inflammatory ophthalmic compositions 05 Mar, 2029
Active
US9433628 Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives 28 Feb, 2029
Active
US11207332 Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives 20 Nov, 2028
Active
US9539262 Ophthalmic composition comprising a prostaglandin 15 Oct, 2028
Active
US7799331 Oral suspension of prednisolone acetate 11 Oct, 2028
Active
US8277780 Stable liquid desoximethasone compositions with reduced oxidized impurity 01 Sep, 2028
Active
US10159682 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives 14 Aug, 2028
Active
US11938141 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives 24 Jul, 2028
Active
US12337002 24 Jul, 2028
Active
US9486458 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives 24 Jul, 2028
Active
US8715624 Stable liquid desoximethasone compositions with reduced oxidized impurity 26 May, 2026
Active
US8143240 17α, 21-dihydroxypregnene esters as antiandrogenic agents 12 Jan, 2026
Active
US8865690 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents 27 Dec, 2025 Expired
US9211295 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents 31 May, 2025 Expired
US7435427 Pharmaceutical semi-solid composition of isotretinoin 21 Sep, 2021 Expired
US8367102 Pharmaceutical semi-solid composition of isotretinoin 21 Sep, 2021 Expired
US8952064 Pharmaceutical semi-solid composition of isotretinoin 21 Sep, 2021 Expired
US9078925 Pharmaceutical semi-solid composition of isotretinoin 21 Sep, 2021 Expired
US9089534 Pharmaceutical semi-solid composition of isotretinoin 21 Sep, 2021 Expired
US7723910 Method of photodynamically diagnosing or treating a contoured surface 17 Jun, 2019 Expired
US6071523 Spill resistant pharmaceutical compositions in semi-solid form 03 Jun, 2018 Expired
US6399079 Spill resistant pharmaceutical compositions in semi-solid form 03 Jun, 2018 Expired
US6656482 Spill resistant pharmaceutical system 03 Jun, 2018 Expired
US6709446 Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light 01 May, 2018 Expired
US8216289 Illuminator for photodynamic therapy 01 May, 2018 Expired
US8758418 Illuminator for photodynamic therapy 01 May, 2018 Expired
US5990100 Composition and method for treatment of psoriasis 24 Mar, 2018 Expired
US5954703 Method and apparatus for applying 5-aminolevulinic acid 31 Oct, 2017 Expired
US5881926 Pharmaceutical compositions in semisolid form and a device for administration thereof 16 Mar, 2016 Expired
US5079262 Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid 30 Sep, 2013 Expired
US6102254 Pharmaceutical compositions in semisolid form and a device for administration thereof 11 Mar, 2013 Expired


Given below is the list of recent legal activities going on the following drug patents of Sun Pharma.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 10 Jul, 2024 US9539262
Electronic Review
Critical
07 Jun, 2024 US11951153
Interim Patent Term Extension Granted
Critical
22 May, 2024 US9211295
Interim Patent Term Extension Granted
Critical
22 May, 2024 US8865690
Payment of Maintenance Fee, 8th Year, Large Entity 08 May, 2024 US9486458
Email Notification
Critical
09 Apr, 2024 US11951153
Mail Patent eGrant Notification 09 Apr, 2024 US11951153
Recordation of Patent eGrant 09 Apr, 2024 US11951153
Recordation of Patent Grant Mailed
Critical
09 Apr, 2024 US11951153
Patent eGrant Notification 09 Apr, 2024 US11951153
Patent Issue Date Used in PTA Calculation
Critical
09 Apr, 2024 US11951153
Payment of Maintenance Fee, 12th Year, Large Entity 02 Apr, 2024 US8277780 (Litigated)
Email Notification
Critical
21 Mar, 2024 US11951153
Issue Notification Mailed
Critical
20 Mar, 2024 US11951153
Application Is Considered Ready for Issue
Critical
07 Mar, 2024 US11951153


Sun Pharma's Drug Patent Litigations

Sun Pharma's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 06, 2013, against patent number US9629852. The petitioner , challenged the validity of this patent, with Ajay Jaysingh Khopade et al as the respondent. Click below to track the latest information on how companies are challenging Sun Pharma's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US11446512 December, 2024 Discretionary Denial
(02 Jul, 2025)
Sun Pharmaceutical Industries, Inc. Biofrontera Incorporated et al.
US11697028 August, 2024 Trial Instituted
(24 Feb, 2025)
Sun Pharmaceutical Industries, Inc. Biofrontera Incorporated et al.
US11697028 April, 2024 Institution Denied
(12 Nov, 2024)
Sun Pharmaceutical Industries, Inc. Biofrontera AG et al.
US10561659 October, 2020 Final Written Decision
(11 May, 2022)
Concert Pharmaceuticals, Inc. Incyte Corporation
US10357567 October, 2021 Terminated
(24 Jan, 2022)
DUSA Pharmaceuticals, Inc. et al. Biofrontera Inc. et al.
US8216289 August, 2018 Institution Denied
(26 Feb, 2019)
DUSA Pharmaceuticals Inc. et al. Biofrontera Incorporated et al.
US8216289 August, 2018 Terminated-Denied
(26 Feb, 2019)
DUSA Pharmaceuticals Inc. Biofrontera Incorporated
US9629852 June, 2013 Decision
(26 Apr, 2016)
Ajay Jaysingh Khopade et al


Sun Pharma Drug Patents' Oppositions Filed in EPO

Sun Pharma drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 08, 2016, by Generics (U.K.) Limited. This opposition was filed on patent number EP13165862A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP15786792A Aug, 2021 Reckitt Benckiser Health Limited Granted and Under Opposition
EP13165862A Jan, 2016 Generics (U.K.) Limited Patent maintained as amended


Sun Pharma's Family Patents

Sun Pharma drugs have patent protection in a total of 58 countries. It's US patent count contributes only to 21.8% of its total global patent coverage. 15 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Recent FDA approvals and tentative approvals for Sun Pharma

This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.

Innovator drugs

Includes innovator drug submissions that appear in FDA approval and tentative approval disclosures.

Drug Name Submission class (FDA) Submission Category Submission Date
Xyrosa ORIG-1
ⓘ
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
Type 3 - New Dosage Form 26 Apr, 2017

Generic drugs

Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.

Drug Name Submission class (FDA) Submission Category Submission Date
Sugammadex ORIG-1
ⓘ
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
- 18 Sep, 2025
Bosutinib ORIG-1
ⓘ
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
- 25 Aug, 2023
Buprenorphine Hydrochloride And Naloxone Hydrochloride ORIG-1
ⓘ
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
- 11 Aug, 2023

Sun Pharma Drug List

Given below is the complete list of Sun Pharma's drugs and the patents protecting them.


1. Absorica

Absorica is protected by 5 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7435427 Pharmaceutical semi-solid composition of isotretinoin 21 Sep, 2021
(4 years ago)
Expired
US8367102 Pharmaceutical semi-solid composition of isotretinoin 21 Sep, 2021
(4 years ago)
Expired
US8952064 Pharmaceutical semi-solid composition of isotretinoin 21 Sep, 2021
(4 years ago)
Expired
US9078925 Pharmaceutical semi-solid composition of isotretinoin 21 Sep, 2021
(4 years ago)
Expired
US9089534 Pharmaceutical semi-solid composition of isotretinoin 21 Sep, 2021
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Absorica's drug page


2. Absorica Ld

Absorica Ld is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9700535 Oral pharmaceutical composition of isotretinoin 04 Aug, 2035
(9 years from now)
Active
US9750711 Low dose oral pharmaceutical composition of isotretinoin 29 May, 2035
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Absorica Ld's drug page


3. Bromsite

Bromsite is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8778999 Non-steroidal anti-inflammatory ophthalmic compositions 07 Aug, 2029
(3 years from now)
Active
USRE50218 Non-steroidal anti-inflammatory ophthalmic compositions 05 Mar, 2029
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bromsite's drug page


4. Bynfezia Pen

Bynfezia Pen is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12350475 29 Dec, 2041
(15 years from now)
Active
US11052196 Method of injecting octreotide acetate into the body 03 Nov, 2040
(14 years from now)
Active
US11246991 Electrolysis-resistant coupling assembly for valves 03 Nov, 2040
(14 years from now)
Active
US11534553 Method of injecting octreotide acetate into the body 03 Nov, 2040
(14 years from now)
Active
US10342850 Octreotide injection 15 May, 2038
(12 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bynfezia Pen's drug page


5. Cequa

Cequa is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10918694 Topical cyclosporine-containing formulations and uses thereof 28 Feb, 2037
(11 years from now)
Active
US11951153 Topical cyclosporine-containing formulations and uses thereof 28 Feb, 2037
(11 years from now)
Active
US10441630 Topical formulations and uses thereof 23 Aug, 2033
(7 years from now)
Active
US8980839 Topical aqueous nanomicellar, ophthalmic solutions and uses thereof 23 Aug, 2033
(7 years from now)
Active
US9937225 Topical formulations and uses thereof 23 Aug, 2033
(7 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cequa's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Drizalma Sprinkle

Drizalma Sprinkle is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10413525 Duloxetine sprinkles 13 Apr, 2037
(11 years from now)
Active
US10959982 Duloxetine sprinkles 13 Apr, 2037
(11 years from now)
Active
US11202772 Duloxetine sprinkles 13 Apr, 2037
(11 years from now)
Active
US12171742 Duloxetine sprinkles 13 Apr, 2037
(11 years from now)
Active
US9839626 Duloxetine sprinkles 13 Apr, 2037
(11 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Drizalma Sprinkle's drug page


7. Ezallor Sprinkle

Ezallor Sprinkle is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10413543 Stable multiparticulate pharmaceutical composition of rosuvastatin 12 Feb, 2036
(10 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ezallor Sprinkle's drug page


8. Flo-pred

Flo-pred is protected by 6 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7799331 Oral suspension of prednisolone acetate 11 Oct, 2028
(2 years from now)
Active
US6071523 Spill resistant pharmaceutical compositions in semi-solid form 03 Jun, 2018
(7 years ago)
Expired
US6399079 Spill resistant pharmaceutical compositions in semi-solid form 03 Jun, 2018
(7 years ago)
Expired
US6656482 Spill resistant pharmaceutical system 03 Jun, 2018
(7 years ago)
Expired
US5881926 Pharmaceutical compositions in semisolid form and a device for administration thereof 16 Mar, 2016
(9 years ago)
Expired
US6102254 Pharmaceutical compositions in semisolid form and a device for administration thereof 11 Mar, 2013
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Flo-pred's drug page


9. Infugem

Infugem is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9241948 Ready to be infused gemcetabine solution 01 Jul, 2033
(7 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Infugem's drug page


10. Leqselvi

Leqselvi is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12364699 10 Oct, 2044
(18 years from now)
Active
US12247034 Crystalline form of deuruxolitinib phosphate 10 May, 2044
(18 years from now)
Active
US12285432 Treatment of hair loss disorders with deuterated JAK inhibitors 11 Aug, 2042
(16 years from now)
Active
US11919907 Deuterated JAK inhibitor and uses thereof 21 May, 2041
(15 years from now)
Active
US10561659 Treatment of hair loss disorders with deuterated JAK inhibitors 04 May, 2037
(11 years from now)
Active
US12076323 Treatment of hair loss disorders with deuterated JAK inhibitors 04 May, 2037
(11 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Leqselvi's drug page


11. Levulan

Levulan is protected by 16 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10357567 Methods for photodynamic therapy 12 Jan, 2038
(12 years from now)
Active
US11077192 Methods for photodynamic therapy 12 Jan, 2038
(12 years from now)
Active
US11135293 Methods for photodynamic therapy 12 Jan, 2038
(12 years from now)
Active
US11571478 Methods for photodynamic therapy 12 Jan, 2038
(12 years from now)
Active
US11690914 Methods for photodynamic therapy 12 Jan, 2038
(12 years from now)
Active
US12296011 Methods for photodynamic therapy 12 Jan, 2038
(12 years from now)
Active
US11446512 Adjustable illuminator for photodynamic therapy and diagnosis 17 Jan, 2037
(11 years from now)
Active
US11179574 Method of administering 5-aminolevulinic acid (ALA) to a patient 13 Oct, 2036
(10 years from now)
Active
US11697028 Adjustable illuminator for photodynamic therapy and diagnosis 13 Oct, 2036
(10 years from now)
Active
US12290700 Adjustable illuminator for photodynamic therapy and diagnosis 13 Oct, 2036
(10 years from now)
Active
US7723910 Method of photodynamically diagnosing or treating a contoured surface 17 Jun, 2019
(6 years ago)
Expired
US6709446 Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light 01 May, 2018
(7 years ago)
Expired
US8216289 Illuminator for photodynamic therapy 01 May, 2018
(7 years ago)
Expired
US8758418 Illuminator for photodynamic therapy 01 May, 2018
(7 years ago)
Expired
US5954703 Method and apparatus for applying 5-aminolevulinic acid 31 Oct, 2017
(8 years ago)
Expired
US5079262 Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid 30 Sep, 2013
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Levulan's drug page


12. Odomzo

Odomzo is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10266523 Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof 30 Mar, 2036
(10 years from now)
Active
US8063043 Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide 15 Sep, 2029
(3 years from now)
Active
US8178563 Compounds and compositions as hedgehog pathway modulators 24 Jul, 2029
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Odomzo's drug page


13. Ortikos

Ortikos is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10172802 Oral pharmaceutical dosage forms of budesonide 09 Sep, 2036
(10 years from now)
Active
US9707182 Oral pharmaceutical dosage forms of budesonide 09 Sep, 2036
(10 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ortikos's drug page


14. Riomet Er

Riomet Er is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9962336 Extended release suspension compositions 01 May, 2035
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Riomet Er's drug page


15. Sezaby

Sezaby is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11857683 Stabilization of phenobarbital sodium for injection 07 Apr, 2042
(16 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sezaby's drug page


16. Topicort

Topicort is protected by 3 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8277780 Stable liquid desoximethasone compositions with reduced oxidized impurity 01 Sep, 2028
(2 years from now)
Active
US8715624 Stable liquid desoximethasone compositions with reduced oxidized impurity 26 May, 2026
(4 months from now)
Active
US5990100 Composition and method for treatment of psoriasis 24 Mar, 2018
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Topicort's drug page


17. Winlevi

Winlevi is protected by 10 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8785427 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives 25 Jul, 2030
(4 years from now)
Active
US9433628 Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives 28 Feb, 2029
(3 years from now)
Active
US11207332 Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives 20 Nov, 2028
(2 years from now)
Active
US10159682 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives 14 Aug, 2028
(2 years from now)
Active
US11938141 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives 24 Jul, 2028
(2 years from now)
Active
US12337002 24 Jul, 2028
(2 years from now)
Active
US9486458 Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives 24 Jul, 2028
(2 years from now)
Active
US8143240 17α, 21-dihydroxypregnene esters as antiandrogenic agents 12 Jan, 2026
(3 days from now)
Active
US8865690 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents 27 Dec, 2025
(12 days ago)
Expired
US9211295 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents 31 May, 2025
(7 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Winlevi's drug page


18. Xelpros

Xelpros is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9629852 Ophthalmic composition comprising a prostaglandin 12 Sep, 2029
(3 years from now)
Active
US9539262 Ophthalmic composition comprising a prostaglandin 15 Oct, 2028
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xelpros's drug page


19. Yonsa

Yonsa is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10292990 Abiraterone steroid formulation 20 May, 2034
(8 years from now)
Active
US9889144 Abiraterone acetate formulation and methods of use 17 Mar, 2034
(8 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Yonsa's drug page